GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDL Biotech AB (XSAT:IDL) » Definitions » EV-to-EBITDA

IDL Biotech AB (XSAT:IDL) EV-to-EBITDA : -17.31 (As of May. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is IDL Biotech AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IDL Biotech AB's enterprise value is kr178.50 Mil. IDL Biotech AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was kr-10.31 Mil. Therefore, IDL Biotech AB's EV-to-EBITDA for today is -17.31.

The historical rank and industry rank for IDL Biotech AB's EV-to-EBITDA or its related term are showing as below:

XSAT:IDL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -129.42   Med: -8.28   Max: 88.3
Current: -17.31

During the past 13 years, the highest EV-to-EBITDA of IDL Biotech AB was 88.30. The lowest was -129.42. And the median was -8.28.

XSAT:IDL's EV-to-EBITDA is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 16.37 vs XSAT:IDL: -17.31

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), IDL Biotech AB's stock price is kr2.88. IDL Biotech AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was kr-0.202. Therefore, IDL Biotech AB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


IDL Biotech AB EV-to-EBITDA Historical Data

The historical data trend for IDL Biotech AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDL Biotech AB EV-to-EBITDA Chart

IDL Biotech AB Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.91 50.15 -51.54 -106.72 -9.48

IDL Biotech AB Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -37.84 -21.63 -9.48 -8.89 -17.37

Competitive Comparison of IDL Biotech AB's EV-to-EBITDA

For the Diagnostics & Research subindustry, IDL Biotech AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDL Biotech AB's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDL Biotech AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IDL Biotech AB's EV-to-EBITDA falls into.



IDL Biotech AB EV-to-EBITDA Calculation

IDL Biotech AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=178.501/-10.31
=-17.31

IDL Biotech AB's current Enterprise Value is kr178.50 Mil.
IDL Biotech AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-10.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDL Biotech AB  (XSAT:IDL) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

IDL Biotech AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.88/-0.202
=At Loss

IDL Biotech AB's share price for today is kr2.88.
IDL Biotech AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.202.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


IDL Biotech AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of IDL Biotech AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


IDL Biotech AB (XSAT:IDL) Business Description

Traded in Other Exchanges
N/A
Address
Karlsbodavagen 39, Stockholm, SWE
IDL Biotech AB develops, produces and markets In Vitro Diagnostic tests for the health care sector. It offers in vitro diagnostic tests within the clinical areas of oncology and bacteriology. The company's trademark products includes TUBEX, TPS, UBC, MonoTotal and TPAcyk.

IDL Biotech AB (XSAT:IDL) Headlines

No Headlines